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existing prevalence and mechanisms of antibiotic resistance (ABR) are all too well known. Several
decades of antibiotic abuse in humans, animals, and agricultural practices have created health emergency
situations and huge socio-economic impact. This paper discusses key ﬁndings of the studies conducted by
several national and international collaborative organizations on the current state of affairs in ABR.
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is discussed.
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It is essential to understand the international scope of antibiotic
resistance (ABR) which is no longer an impending threat in any
one part of the world; in fact, it is happening globally and poses
unimaginable risks to animal health. Currently, there is no
systematic international surveillance of ABR, but leading organi-
zations and governments across the world are developing coordi-
nated action plans to effectively control and manage the risks
involved, many of which are discussed here. However, an accurate
determination of the magnitude of ABR on a global scale is a
complex and multidimensional task which is nearly impossible to
achieve using currently invested resources. Nevertheless, there
have been encouraging developments1–4 in last few years. The
developed world seems to have woken to the perils of ABR and
accordingly formulated stiff policies and stimulated surveillance
methods, but the developing world is yet to show a hard line
systematic approach in their ﬁght against ABR. As a comparison,
available reports have estimated a per annum death toll of 23,000
in the US4, 25,000 in EU3, and 58,0001 in India from various drug
resistant bacterial infections.
The 2013 World Health Organization's (WHO) report2 was the
ﬁrst most comprehensive and closest to ground-zero analysis on
ABR. The European Union3 and the Centers for Disease Control
and Prevention (CDC)4 reports also provide their territorial over-
view of the situation. The latest of all is a 2015 report by Global
Antibiotic Resistance Partnership (GARP)1.2. Global antibiotic resistance partnership (GARP) report—
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GARP fostered the initiation of a dialog for coordinated antibiotic
policy in eight countries which led to the development of a
comprehensive world antibiotics report that discusses global
patterns in ABR and use, policy interventions and state of R&D
pipeline for new drugs. Not surprisingly, according to their 2015
report—The State of World's Antibiotics, resistance patterns differ
country wise and mirror the use of antibiotics and disease patterns.
The good news is, US, Europe, Canada, and South Africa have
reported a decline in methicillin-resistant Staphylococcus aureus
(MRSA) infections over the past few years, while on the reverse,
sub-Saharan Africa, Australia, Latin America (90%) and India
(47%) have reported increase in MRSA infections. Across the
world, third and fourth generation cephalosporin resistant Escher-
ichia Coli are becoming difﬁcult to treat due to their ability to
secrete extended-spectrum β-lactamase (ESBLs). In 2013, 17 out
of 22 European countries reported 85% to 100% of ESBL positive
E. coli isolates (European Antimicrobial Resistance Surveillance
Network, EARS-Net, 2014). In 2009 and 2010, 28% of the E. coli
family (Enterobacteriacae) from 11 Asian countries was reported
to be ESBL producers, and their resistance to third- and fourth-
generation cephalosporins ranged between 26% and 50%.
There are wide variations in global data for carbapenem-
resistant enterobacteriacae (CRE) family. Carbapenems are last-
resort antibiotics used against bacteria resistant to ﬁrst-, second-
and third-line antibiotics. CRE resistance seems to have remained
stable in Canada (2015), in EU some countries have reported an
increase, but largely limited to 10% for Klebsiella pneumoniae and
under 1% for E. coli (2013–2014). The US reported 11%
resistance for Klebsiella spp. and 2% of E. coli isolates (2013).
India reported a steep increase in K. pneumoniae resistance, from29% (2008) to 57% (2014) and for E. coli resistance increased
from 10% (2008) to 13% (2013). Overall, the GARP data suggests
higher risks of ABR in developing countries due to higher
numbers of immunocompromised patients, inaccessibility to sec-
ond- and third-line drugs, poor hygiene, unreliable quarantine
measures and policy implementation issues.
However, the positive strategic and policy developments on a
global scale have persuaded various countries to adopt strict
measures. Plans are being formulated to control, prevent and
monitor ABR. For example, in 2015, the World Health Assembly
endorsed the Global Action Plan on Antimicrobial Resistance and
invited all countries to adopt national strategies for ABR control,
prevention, and monitoring within two years. The same year, US
President formulated a National Action Plan for Combating
Antibiotic-Resistant Bacteria. The European Union and Southeast
Asian WHO countries have also committed to addressing the
issue. Countries like China, India, South Africa, Vietnam, Philip-
pines, Australia, and New Zealand have also set up national
surveillance bodies which collect, track and report ABR trends.3. World Health Organization—20142
WHO's report—Antimicrobial Resistance, Global Report on
Surveillance—provides an extensive global review of ABR
including surveillance and resistance data for bacteria that are
classiﬁed as “bacteria of international concern”. A detailed review
of health and economic burden of ABR, the challenges in
surveillance, and proposed future directions for its control and
prevention are discussed. Not so surprisingly, the key ﬁndings in
this report are largely inﬂuenced by the availability of data and
different surveillance methodologies used in various regions. The
European region (74%) and east Mediterranean region (32%) are
the best and worst suppliers of ABR data, while others fall in
between. The data contributions for other regions are: Americas
(60%), west paciﬁc (70%), south-east Asia (55%) and Africas
(49%). As a result, the key ﬁndings, when viewed in light of the
differences in data availability from various regions, provide an
inconclusive picture. This is due to the added challenge of
identifying the extent to which such differences in reported data
reﬂect real differences in resistance patterns for drug-antibacterial
agents, or are attributable to differences in sampling of patients,
laboratory performance and methodology, etc. However, it is
important to rest our focus on the ﬁndings which are insightful.
The WHO has classiﬁed seven bacteria of international concern;
their identiﬁcation and resistance overview is given below:
 E. coli: resistant to third-generation cephalosporins, extended
spectrum β-lactamases (ESBLs), and ﬂuoroquinolones; K. pneumoniae: resistant to third-generation cephalosporins,
including ESBLs, and carbapenems; S. aureus: resistant to β-lactam antibacterial drugs
(methicillin, MRSA); Staphylococcus pneumoniae: resistant or nonsusceptible to
penicillin (or both); Non-typhoidal Salmonella (NTS): resistant to ﬂuoroquinolones; Shigella species: resistant to ﬂuoroquinolones; and Neisseria gonorrhoeae: decreased susceptibility to third-
generation cephalosporins.
It is worth noting that for E. coli, K. pneumoniae and S. aureus,
the proportion of bacteria resistant to commonly used speciﬁed
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WHO regions found K. pneumoniae resistant to carbapenems,
usually the last line of available treatment, with reports in
European and Mediterranean region exceeding 50%. Most WHO
regions reported MRSA proportions exceeding 20%, and some
exceeding 80%. Non-susceptibility to penicillin has been detected
in all WHO regions.4. European Center for Disease Prevention and Control
(ECDC)—20143
ECDC is the European Union's main surveillance system on
antimicrobial resistance. It has led the efforts and created a
European antimicrobial resistance surveillance interactive database
(EARS-Net) that provides annually updated information on the
occurrence and spread of resistance in European countries and
releases annual reports. Their 2014 report—Antimicrobial Resis-
tance Surveillance in Europe—summarizes the resistance patterns
for the following challenging bacteria: E. coli, K. pneumoniae,
Pseudomonas aeruginosa, Acinetobacter species, Streptococcus
pneumoniae, S. aureus, and Enterococci.
ECDC reported an “especially worrying” situation for Gram-
negative bacteria due to high and increasing resistance percentages
reported from many parts of Europe. High resistance increase to
third generation cephalosporins (often in combination with ﬂuor-
oquinolone and aminoglycoside resistance) was observed in
K. pneumoniae and E. coli between 2011 and 2014. A 7.4%
increase in carbapenem resistance in K. pneumoniae was observed
in 2014, although carbapenem resistance in E. coli remained rare.
In K. pneumoniae, the most common resistance phenotype was
found resistant to three key antimicrobial groups: ﬂuoroquino-
lones, third-generation cephalosporins and aminoglycosides.
For Gram-positive bacteria such as for MRSA, the resistance
trends have decreased from 18.6% in 2011 to 17.4% in 2014. The
resistance percentages for S. pneumoniae have remained stable
from 2011 to 2014, and it remained less susceptible to macrolides
than penicillin. In 2014, an increase in vancomycin-resistant
Enterococci was reported since 2004. P. aeruginosa isolates also
showed resistance, with a majority of countries reporting resis-
tance percentages above 10% for all antimicrobial groups under
surveillance, including carbapenems, ﬂuoroquinolines and amino-
glycosides. Carbapenem resistance in P. aeruginosa was recorded
to vary between 4.4% and 58.5% in 2014. Resistance patterns for
MRSA showed wide intercountry variations in Europe, ranging
from 0.9% to 56.0%. Notably, the weighted mean MRSA
percentage decreased from 18.6% in 2011 to 17.4% in 2014.
However, 7 out of 29 countries reported MRSA percentages above
25%, and despite the overall positive development on MRSA
front, EU classiﬁes MRSA as a public health priority in Europe.
Notably, vancomycin resistance in Enterococcus faecium showed
an increase from 2011 to 2014 due to which it remains a major
infection control challenge.5. US Centre for Disease Control and Prevention (CDC)—
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In 2013, the CDC in their report—Antibiotic Resistance Threats in
the United States—classiﬁed ABR as a complex problem having
potentially catastrophic consequences of inaction. CDC provided
what they called "conservative and minimum" estimates of morethan two million people sickened every year with ABR infections
in the US causing at least 23,000 deaths.
The US's premier health agency prioritized bacteria according
to the concern-levels, namely: urgent, serious, and concerning.
Urgent bacteria are deﬁned as those with high-consequence
antibiotic-resistant threats because of signiﬁcant risks identiﬁed.
These may not be currently widespread but have the potential to
become so and therefore require urgent public health attention.
These include Clostridium difﬁcile, Carbapenem-resistant Enter-
obacteriaceae (CRE), and drug-resistant Neisseria gonorrhoeae.
C. Difﬁcile requires urgent and aggressive actions and causes
14,000 deaths, 250,000 infections per annum, resulting in more
than one billion excess medical costs. It spreads quickly being
naturally resistant to a large number of antibiotics and has
developed resistance to ﬂuoroquinolones. CREs, such as Kleb-
siella species and E. coli, have become resistant to all or nearly all
antibiotics, including carbapenems, causing 600 deaths and
sickening 9000 people every year in the US. N. gonorrhoeae
causes 246,000 drug-resistant infections every year and is showing
resistance to antibiotics usually used to treat it, including ceﬁxime
(an oral cephalosporin), ceftriaxone (an injectable cephalosporin),
azithromycin, and tetracycline.
Serious bacteria are recognized as signiﬁcant antibiotic resistant
threats having low/declining incidences and reasonable availability
of drugs, but if left unmonitored may become urgent in near future.
These include various drug resistant strains of Acinetobacter,
Campylobacter, ﬂuconazole-resistant Candida (a fungus),
extended spectrum β-lactamase producing Enterobacteriaceae
(ESBLs), vancomycin-resistant Enterococcus (VRE), P. aerugi-
nosa, non-typhoidal Salmonella, Salmonella typhi, Shigella,
MRSA, S. pneumoniae, and Sternoclavicular tuberculosis.
Concerning bacteria are those with low ABR having multiple
drug options available for resistant strains, but cause severe illness
and require monitoring. These include vancomycin-resistant
S. aureus (VRSA), erythromycin-resistant Group A Streptococcus,
and clindamycin-resistant Group B Streptococcus.
Importantly, within the US, multidrug-resistant and extensively
drug-resistant tuberculosis (MDR and XDR TB) infections are not
an immediate and urgent threat, unlike developing countries in
south-east Asia, because such infections are uncommon due a
robust prevention and control program. Same is true for MRSA
because at present there are multiple effective antibiotics for
treating infections but if the strains become more resistant then
MRSA may change from a serious to an urgent threat.
The above discussion provides an overview of the ABR threat
on a global scale as recorded by the leading health agencies across
the world. Below, let us put this information in perspective and
look at the antibacterial drugs approved in last ﬁve years by the
United States' Food and Drug Administration (US FDA).6. Antibacterial agents/antibiotics approved by the US FDA
from 2011 to 20165
Table 1 shows a list of drugs approved by the US FDA for sale in
the United States from 2011 to 2016. Effectively targeting drug
resistance requires use of antibacterial agents with novel mechan-
ism of action. Between 1930 and 1962, the antibiotic industry was
fertile and twenty new classes of drugs made it to the market.
Since 1960s, only three entirely new classes of drugs were
approved; however, numerous analogs have made it to the market.
Consequently, drugs have become less effective and bacteria more
Table 1 Drugs approved by FDA from 2011–2016.
Drug Indication Company (year)
Avycaz
(ceftazidime–avibactam)
For complicated intra-abdominal and urinary tract infections caused by E. coli,
K. pneumoniae, C. koseri, E. aerogenes, E. cloacae, C. freundii, Proteus
spp., and P. aeruginosa
Actavis
(February 2015)
Dalvance
(dalbavancin)
For acute bacterial skin and skin structure infections caused by S. aureus
(including methicillinsusceptible and methicillin-resistant strains),
S. pyogenes, S. agalactiae, and S. anginosus
Durata Therapeutics
(May 2014)
Metronidazole
1.3% Vaginal Gel
For the treatment of bacterial vaginosis caused by anaerobic bacteria and
protozoa
Actavis, Inc.
(April 2014)
Orbactiv
(oritavancin)
For acute bacterial skin and skin structure infections S. aureus (including
methicillin-susceptible and methicillin-resistant isolates), S. pyogenes,
S. agalactiae, S. dysgalactiae, S. anginosus group (including S. anginosus,
S. intermedius, and S. constellatus), and E. faecalis (vancomycin-
susceptible isolates only).
The Medicines Company
(August 2014)
Sivextro
(tedizolid phosphate)
For acute bacterial skin and skin structure infections. S. aureus (including
MRSA and methicillin-susceptible [MSSA] isolates), S. pyogenes, S.
agalactiae, S. anginosus Group (including S. anginosus, S. intermedius,
and S. constellatus), and E. faecalis.
Cubist Pharmaceuticals
(June 2014)
Sirturo
(bedaquiline)
For multi-drug resistant tuberculosis Janssen Therapeutics
(December 2012)
Abthrax
(raxibacumab)
For Anthrax GlaxoSmithKline
(December 2012)
Diﬁcid
(ﬁdaxomicin)
For C. difﬁcile-associated diarrhea Optimer Pharmaceuticals
(May 2011)
C. difﬁcile, Clostridium difﬁcile; C. freundii, Citrobacter freundii; C. koseri, Citrobacter koseri; E. coli, Escherichia coli; E. faecalis, Enterococcus
faecalis; E. aerogenes, Enterobacter aerogenes; E. cloacae, Enterobacter cloacae; K. pneumoniae, Klebsiella pneumoniae; P. aeruginosa,
Pseudomonas aeruginos; S. agalactiae, Streptococcus agalactiae; S. anginosus, Streptococcus anginosus; S. aureus, Staphylococcus aureus; S.
constellatus, Streptococcus constellatus; S. intermedius, Streptococcus intermedius; S. pyogenes, Streptococcus pyogenes; S. agalactiae,
Streptococcus agalactiae; S. anginosus, Streptococcus anginosus; S. constellatus, Streptococcus constellatus; S. dysgalactiae, Streptococcus
dysgalactiae; S. intermedius, Streptococcus intermedius.
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are needed for antibiotics to be working effectively for next ﬁfty
years5,6. At present, not even enough analogs are making it
through FDA approvals. In last ﬁve years, a meager eight
antibiotics were approved as discussed below:
6.1. Avycaz
A third generation cephalosporin combination drug having two
components, ceftazidime and avibactam. Ceftazidime is an anti-
bacterial drug which binds to penicillin binding proteins and works
against certain Gram-negative and Gram-positive bacteria. Avi-
bactam is a non-betalactam beta-lactamase inhibitor which inacti-
vates β-lactamases and protects ceftazidime from degradation.
6.2. Dalvance (dalbavancin)
This is indicated for adult-use only, those having acute bacterial
skin infections. It works against several Gram-positive bacteria
including S. aureus (including methicillin-susceptible and
methicillin-resistant strains). Dalbavancin, is a semisynthetic
lipoglycopeptide that binds to the D-alanyl-D-alanine residues
interfering with cell wall synthesis and preventing cross-linking.
6.3. Metronidaozle
This is a nitroimidazole antibiotic used for treatment of anaerobic
bacteria and protozoa causing bacterial vaginosis in non-
pregnant women.6.4. Orbactiv (oritavancin)
It is semisynthetic lipoglycopeptide antibacterial drug having
bactericidal activity against S. aureus, Streptococcus pyogenes,
and Enterococcus faecalis including MRSA.6.5. Sivextro (tedizolid phosphate)
This belongs to oxazolidinone class and is indicated for the
treatment of adults with acute bacterial skin and skin structure
infections. Tedizolid binds to the 50S subunit of the bacterial
ribosome resulting in inhibition of protein synthesis.6.6. Sirturo (bedaquiline)
It is a diarylquinoline antimycobacterial drug that inhibits myco-
bacterial ATP (adenosine 5ʹ-triphosphate) synthase in Mycobacter-
ium tuberculosis. This is used in combination therapy in adults
with pulmonary multi-drug resistant tuberculosis.6.7. Abthrax (raxibacumab)
Abthrax is a monoclonal antibody approved for the treatment and
prevention of inhalational anthrax when alternative therapies are
not available or appropriate.
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A narrow spectrum macrocyclic antibiotic used for treating adults
having Clostridium difﬁcile–associated diarrhea. It works by
inhibition of RNA synthesis.7. Conclusions
The currently available estimates of ABR burden in each country
point to an evident conclusion that it is in the self interest of each
country to prolong antibiotic effectiveness within their territories.
The pipeline of new antibacterial agents is especially discouraging
and it has been so for the last few decades. Several reasons are
attributed to this grim scenario of drug discovery for new
antibiotics. The major one however is the lacking interest of
pharma companies. Finding it hard to recoup drug discovery costs
from antibiotics which develop resistance within a decade or so,
pharmaceutical companies preferably choose to invest in safer
types of drugs, such as antidepressants, statins, and anti-
inﬂammatory medications, which can bring steady ﬂow of
revenue, even when off-patent. Although, academic laboratories
appear to continue their research efforts in looking for new drug
leads, their efforts are inadvertently quashed by their inability to
collaborate with the pharma companies for conducting high level
pre-clinical research, and also their failure to transfer/license such
technologies beyond academic laboratories. Such setbacks cost
dearly to the new antibiotic discovery, because academic labora-
tories lack the resources and funding to carry out top gear research
on their own. This symbiotic relationship of academic labs and
pharma industry needs to be lessened by increasing the amount of
federal funding to the universities. It so appears that the govern-
ment has begun efforts to lure pharmaceutical companies back into
the antibiotic research by facilitating fast-track FDA approvals,
providing extended drug-patent exclusivity of ﬁve years, which is
evidenced by the Generating Antibiotic Incentives Now (GAIN)
Act, a new law brought about in 2012 by the US government;
although, the results of it remain to be seen in coming years.
For now, the future of antibiotic discovery is uncertain, and
therefore we need to lessen our anticipation of a robust antibacter-
ial drug pipeline and with that our hopes for a drastic upsurge in
ABR drug discovery trends in near future. In fact, preventive
measures can go a long way in tackling ABR effectively and
appear to be a reasonable solution to the problem until some
radical innovation transforms the antibacterial drug pipeline
towards betterment.
All countries, especially the developing ones, in the context of
antibiotics, need to institute methods for the appropriate choice ofdrug treatment—a complex problem involving prescribers, dis-
pensers, and consumers. The most necessary component, the
diagnostic aspect of drug prescription, is often ignored in many
countries. It is important that bacterial culture and susceptibility
testing before antibacterial prescription are mandated. Drug quality
plays an important role too and needs serious enforcement
measures. This is a particularly common problem with generic
drug makers in developing countries. Sub-optimal amounts of drug
invariably lead to drug resistance; therefore quality control
measures of drug labels are important. At the same time,
educational interventions at the patient level play a critical role.
Most importantly, controlling the spread of resistant organisms
using proper quarantine measures will have a tremendous additive
effect on the prevention of ABR dissemination. For example, in
case of outbreaks, countries must be ready with pre-specialized
task forces to prevent the introduction and transmission of
infective agents, especially amongst mobile population. The
“search and destroy” policy involving patient pre-screening,
isolating, quarantining, staff member screening, has been proven
effective in many countries. Similar approaches should be tailored
speciﬁc to the needs of each region and outbreak type, and must be
pre-instituted and ready-at-use at the eleventh hour. It is also
important to realize that each country faces its unique challenges in
ABR and therefore needs to proactively review their own precise
problems and ﬁnd solution applicable within their boundaries.References
1. Gelband H, Miller-Petrie M, Pant S, Gandra S, Levinson J, Barter D, et
al. The state of the world's antibiotics—2015 [cited 05.03.16]. Available
at: 〈https://cddep.org/sites/default/ﬁles/swa_2015_ﬁnal.pdf〉.
2. World Health Organization. Antimicrobial resistance global report on
surveillance [cited 10.03.16]. Available at: 〈http://apps.who.int/iris/
bitstream/10665/112642/1/9789241564748_eng.pdf〉.
3. The European Centre for Disease Prevention and Control. Antimicrobial
resistance surveillance in Europe. Annual report of the European
Antimicrobial Resistance Surveillance Network (EARS-Net)—2014,
[cited 18.02.16]. Available at: 〈http://ecdc.europa.eu/en/publications/
Publications/antimicrobial-resistance-europe-2014.pdf〉.
4. U.S. Department of Health and Human Services. Centers of Disease
Control and Prevention. Antibiotic resistance threats in the United
States, 2013 [cited 10.02.16]. Available at: 〈http://www.cdc.gov/drugre
sistance/pdf/ar-threats-2013-508.pdf〉.
5. 2016 FDA Approved Drugs. [cited 15.03.16]. Available at: 〈http://
www.centerwatch.com/drug-information/fda-approved-drugs〉.
6. Coates RMA, Halls G, Hu Y. Novel classes of antibiotics or more of the
same? Br J Pharmacol 2011;163:184–94.
